Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index

References

• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292–1300. doi:10.1111/j.1398-9995.2008.01750.x
   PubMed Web of Science ®Google Scholar
• Juel-Berg N, Darling P, Bolvig J, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28. doi:10.2500/ajra.2016.30.4397
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1–S84. doi:10.1016/j.jaci.2008.06.003
   PubMed Web of Science ®Google Scholar
• Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol. 2001;108(1 Suppl):S59–S64. doi:10.1067/mai.2001.115568
   PubMed Web of Science ®Google Scholar
• Bensch GW. Safety of intranasal corticosteroids. Ann Allergy Asthma Immunol. 2016;117(6):601–605. doi:10.1016/j.anai.2016.06.009
   PubMed Web of Science ®Google Scholar
• Sheth K. Evaluating the safety of intranasal steroids in the treatment of allergic rhinitis. Allergy Asthma Clin Immunol. 2008;4(3):125–129. doi:10.1186/1710-1492-4-3-125
   PubMedGoogle Scholar
• Şimşek A, Bayraktar C, Doğan S, Karataş M, Sarıkaya Y. The effect of long-term use of intranasal steroids on intraocular pressure. Clin Ophthalmol. 2016;10:1079–1082. doi:10.2147/OPTH.S106392
   PubMedGoogle Scholar
• Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:Cd011993.
   PubMed Web of Science ®Google Scholar
• Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol. 1999;104(4 Pt 1):S144–149. doi:10.1016/S0091-6749(99)70310-6
   Web of Science ®Google Scholar
• Hankin CS, Cox L, Lang D, et al. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. Allergy Asthma Proc. 2012;33(3):258–264. doi:10.2500/aap.2012.33.3565
   Web of Science ®Google Scholar
• Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2007;98(1):12–21. doi:10.1016/S1081-1206(10)60854-X
   Web of Science ®Google Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380. doi:10.1111/bcp.12637
   PubMed Web of Science ®Google Scholar
• Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999;104(4 Pt 1):S150–158. doi:10.1016/S0091-6749(99)70311-8
   Web of Science ®Google Scholar
• Schafer T, Schnoor M, Wagenmann M, Klimek L, Bachert C. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011;49(3):272–280.
   Web of Science ®Google Scholar
• Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol. 2007;21(1):70–79. doi:10.2500/ajr.2007.21.2896
   PubMedGoogle Scholar
• van Cauwenberge P, Van Hoecke H, Vandenbulcke L, Van Zele T, Bachert C. Glucocorticosteroids in allergic inflammation: clinical benefits in allergic rhinitis, rhinosinusitis, and otitis media. Immunol Allergy Clin North Am. 2005;25(3):489–509. doi:10.1016/j.iac.2005.05.001
   Web of Science ®Google Scholar
• Esmailpour N, Högger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int Arch Allergy Immunol. 2000;122(2):151–154. doi:10.1159/000024371
   PubMed Web of Science ®Google Scholar
• Baumann D, Bachert C, Högger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540–1550. doi:10.1111/j.1365-2222.2009.03306.x
   PubMed Web of Science ®Google Scholar
• Bardsley G, Daley-Yates P, Baines A, et al. Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial. Respir Res. 2018;19(1):133. doi:10.1186/s12931-018-0836-6
   Web of Science ®Google Scholar
• Daley-Yates P, Brealey N, Kumar B, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2020;87(2):1–11. doi:10.1111/bcp.14406.
   Web of Science ®Google Scholar
• Stellato C, Atsuta J, Bickel CA, Schleimer RP. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol. 1999;104(3 Pt 1):623–629. doi:10.1016/S0091-6749(99)70334-9
   Web of Science ®Google Scholar
• Kirtsreesakul V, Chansaksung P, Ruttanaphol S. Dose-related effect of intranasal corticosteroids on treatment outcome of persistent allergic rhinitis. Otolaryngol Head Neck Surg. 2008;139(4):565–569. doi:10.1016/j.otohns.2008.07.023
   Web of Science ®Google Scholar
• Meltzer EO, Orgel HA, Bronsky EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol. 1990;86(2):221–230. doi:10.1016/S0091-6749(05)80069-7
   Web of Science ®Google Scholar
• Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3):313–321. doi:10.2500/aap.2008.29.3126
   Web of Science ®Google Scholar
• Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(5):497–505. doi:10.1016/S1081-1206(10)60477-2
   PubMed Web of Science ®Google Scholar
• Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119(6):1430–1437. doi:10.1016/j.jaci.2007.02.022
   PubMed Web of Science ®Google Scholar
• Nielsen LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs. 2001;61(11):1563–1579. doi:10.2165/00003495-200161110-00004
   PubMed Web of Science ®Google Scholar
• Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25(8):2021–2041. doi:10.1185/03007990903094106
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23(1):11–33. doi:10.2165/00002018-200023010-00002
   PubMed Web of Science ®Google Scholar
• Schipper NG, Verhoef JC, Merkus FW. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res. 1991;8(7):807–814. doi:10.1023/A:1015830907632
   Web of Science ®Google Scholar
• Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106(4 Suppl):S179–190. doi:10.1067/mai.2000.110038
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004;60(4):265–268. doi:10.1007/s00228-004-0763-y
   PubMed Web of Science ®Google Scholar
• Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(1 Suppl):S26–31. doi:10.1067/mai.2001.115563
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol. 2001;51(1):103–105. doi:10.1046/j.1365-2125.2001.01325.x
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001;51(5):400–409. doi:10.1046/j.0306-5251.2001.01374.x
   PubMed Web of Science ®Google Scholar
• Dluhy RG. Clinical relevance of inhaled corticosteroids and HPA axis suppression. J Allergy Clin Immunol. 1998;101(4 Pt 2):S447–S450. doi:10.1016/S0091-6749(98)70157-5
   Web of Science ®Google Scholar
• Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther. 2004;26(11):1905–1919. doi:10.1016/j.clinthera.2004.11.017
   PubMed Web of Science ®Google Scholar
• Daley-Yates P, Richards DH. Pharmacokinetics (PK) and Pharmacodynamic (PD) relationships for Intranasal Corticosteroids (INCS). J Allergy Clin Immunol. 2001;107(2, Supplement):S313.
   Web of Science ®Google Scholar
• Kimmerle R, Rolla AR. Iatrogenic Cushing’s syndrome due to dexamethasone nasal drops. Am J Med. 1985;79(4):535–537. doi:10.1016/0002-9343(85)90046-4
   Web of Science ®Google Scholar
• Donaldson AM, Choby G, Kim DH, Marks LA, Lal D. Intranasal corticosteroid therapy: systematic review and meta-analysis of reported safety and adverse effects in adults. Otolaryngol Head Neck Surg. 2020;163(6):1097–1108. doi:10.1177/0194599820931455
   PubMed Web of Science ®Google Scholar
• Pedersen S. Assessing the effect of intranasal steroids on growth. J Allergy Clin Immunol. 2001;108(1 Suppl):S40–S44. doi:10.1067/mai.2001.115565
   PubMed Web of Science ®Google Scholar
• Mener DJ, Shargorodsky J, Varadhan R, Lin SY. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. Int Forum Allergy Rhinol. 2015;5(2):95–103. doi:10.1002/alr.21430
   PubMed Web of Science ®Google Scholar
• Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23. doi:10.1542/peds.105.2.e23
   PubMed Web of Science ®Google Scholar
• Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr. 1993;82(8):635–640. doi:10.1111/j.1651-2227.1993.tb18030.x
   PubMed Web of Science ®Google Scholar
• Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22. doi:10.1542/peds.105.2.e22
   PubMed Web of Science ®Google Scholar
• Möller C, Ahlström H, Henricson KA, Malmqvist LA, Akerlund A, Hildebrand H. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy. 2003;33(6):816–822. doi:10.1046/j.1365-2222.2003.01689.x
   Web of Science ®Google Scholar
• Murphy K, Uryniak T, Simpson B, O’Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol. 2006;96(5):723–730. doi:10.1016/S1081-1206(10)61072-1
   PubMed Web of Science ®Google Scholar
• Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther. 2007;29(8):1738–1747. doi:10.1016/j.clinthera.2007.08.017
   PubMed Web of Science ®Google Scholar
• Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312–319. doi:10.1136/thoraxjnl-2013-203600
   PubMed Web of Science ®Google Scholar
• Lee LA, Sterling R, Máspero J, Clements D, Ellsworth A, Pedersen S. Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract. 2014;2(4):421–427. doi:10.1016/j.jaip.2014.04.008
   PubMed Web of Science ®Google Scholar
• Williams B, Smith WB, Kette FE. Intranasal ciclesonide for allergic rhinitis. J Asthma Allergy. 2008;1:49–54.
   Google Scholar
• Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008;121(1):e1–e14. doi:10.1542/peds.2006-2206
   Web of Science ®Google Scholar
• Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133428. doi:10.1371/journal.pone.0133428
   PubMed Web of Science ®Google Scholar
• Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904–912. doi:10.1056/NEJMoa1203229
   PubMed Web of Science ®Google Scholar
• de Groot EP, Nijkamp A, Duiverman EJ, Brand PLP. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax. 2012;67(7):582–587. doi:10.1136/thoraxjnl-2011-201168
   PubMed Web of Science ®Google Scholar
• Allen DB. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist’s perspective. Acta Paediatr. 1998;87(2):123–129. doi:10.1111/j.1651-2227.1998.tb00960.x
   Web of Science ®Google Scholar
• de Benedictis FM, Teper A, Green RJ, Boner AL, Williams L, Medley H. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch Pediatr Adolesc Med. 2001;155(11):1248–1254. doi:10.1001/archpedi.155.11.1248
   PubMed Web of Science ®Google Scholar
• Sheth KK, Cook CK, Philpot EE, et al. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc. 2004;25(2):115–120.
   PubMed Web of Science ®Google Scholar
• Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(39 Suppl):1–34. doi:10.1111/j.1398-9995.1997.tb05047.x
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998;157(3 Pt 2):S1–53. doi:10.1164/ajrccm.157.3.157315
   PubMed Web of Science ®Google Scholar
• Administration FaD. Guidance for industry orally inhaled and intranasal corticosteroids: evaluation of the effects on growth in children; March 2007.
   Google Scholar
• Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther. 2007;29(7):1415–1420. doi:10.1016/j.clinthera.2007.07.028
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Veramyst prescribing information; 2011.
   Google Scholar
• GlaxoSmithKline. Flonase prescribing information; 2019.
   Google Scholar
• Merck. Nasonex. Summary of product Characteristics; 2020.
   Google Scholar
• Sunovion Pharmaceuticals. Omnaris. Prescribing information; 2013.
   Google Scholar
• Sanofi-aventis. Nasacort AQ prescribing information; 2013.
   Google Scholar
• Bausch and Lomb. Flunisolide nasal solution. Prescribing information; 2016.
   Google Scholar
• AstraZeneca. Rhinocort. Prescribing information; 2010.
   Google Scholar
• Sandoz Limited. Budesonide. Summary of product characteristics; 2021.
   Google Scholar
• GlaxoSmithKline. Beconase AQ nasal spray. Prescribing information; 2015.
   Google Scholar
• Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54. doi:10.1186/1465-9921-8-54
   Web of Science ®Google Scholar
• Weiswasser M, Zhu J, Chia V, et al. Low systemic bioavailability of ciclesonide aqueous nasal spray and ciclesonide HFA nasal aerosol compared with orally inhaled ciclesonide. J Allergy Clin Immunol. 2008;121(2):S53. doi:10.1016/j.jaci.2007.12.214
   Web of Science ®Google Scholar